vTv Therapeutics
VTVT
24 hedge funds and large institutions have $3.76M invested in vTv Therapeutics in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 10 reducing their positions, and 8 closing their positions.
0.05% less ownership
Funds ownership: 0.24% → 0.19% (-0.05%)
17% less funds holding
Funds holding: 29 → 24 (-5)
43% less capital invested
Capital invested by funds: $6.55M → $3.76M (-$2.78M)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
90% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 10
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$32.2K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$17.3K |
| 3 |
Renaissance Technologies
New York
|
+$8.57K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.84K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$830K |
| 2 |
Morgan Stanley
New York
|
-$129K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$94K |
| 4 |
VF
Virtu Financial
New York
|
-$94K |
| 5 |
Rafferty Asset Management
New York
|
-$69K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Citadel Advisors
Miami,
Florida
| – | -$94K | -2,353 | Closed |
|
|
27
Rafferty Asset Management
New York
| – | -$69K | -1,727 | Closed |
|
28
Bank of America
Charlotte,
North Carolina
| – | -$22K | -556 | Closed |
|
|
ECM
29
ExodusPoint Capital Management
New York
| – | -$22K | -553 | Closed |
|
30
UBS Group
Zurich,
Switzerland
| – | -$17K | -422 | Closed |
|
31
Jane Street
New York
| – | -$14K | -349 | Closed |
|
32
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$30 | -1 | -20% |
|
VTVT Hedge Fund Activity: Q1 2022 in Review
24 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q1 2022, worth a combined $3.76M — down 43% from $6.55M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of VTVT and 3 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 1 added.
The largest buyer was Ikarian Capital, adding an estimated $32.2K. The largest seller was EcoR1 Capital, exiting entirely with an estimated $830K sold.
- 24 institutional investors held vTv Therapeutics (VTVT) as of Q1 2022, down from 29 in Q4 2021.
- Funds reported $3.76M of vTv Therapeutics stock for Q1 2022, down 43% quarter-over-quarter.
- 3 funds opened new vTv Therapeutics positions in Q1 2022 and 8 closed out, a net change of -5 holders.
- The largest vTv Therapeutics buyer in Q1 2022 was Ikarian Capital, an estimated $32.2K added.
- The largest vTv Therapeutics seller in Q1 2022 was EcoR1 Capital, an estimated $830K sold.
Based on aggregated 13F filings for Q1 2022.